| Coronavirus fears have snowballed into travel restrictions across the industry, disrupting plans for several upcoming meetings—with many being called off in favor of virtual get-togethers. Big Pharmas like GSK, BMS, Roche and Sanofi all grounded their employees, as have the cancer centers Dana-Farber and MD Anderson. Meanwhile Biogen, unfortunately, is serving as precedent: its Boston management meeting is at the center of Massachusetts’ outbreak, linked to about 80 cases. Those stories follow below, plus our other top reads of the week, and FierceMedTech’s annual Fierce 15, featuring companies tackling different aspects of the coronavirus and a host of other conditions. | |
|
Featured Story | | | Friday, March 6, 2020 Biopharma companies are hunkering down as the COVID-19 epidemic breaks out worldwide. GlaxoSmithKline, Bristol Myers, Boehringer Ingelheim and more are restricting travel around the world, limiting gatherings and requiring some vendors to do the same. |
|
|---|
|
|  | [Survey] Bioavailability Toolkit Share insight on the drug developer’s perspective on bioavailability enhancement technologies and the reasoning behind the use of certain technologies in preclinical and early-stage clinical development. Take the survey. |
Top Stories Of The Week Monday, March 9, 2020 The Bill & Melinda Gates Foundation has made new commitments to respond to the spread of the novel coronavirus in its hometown of Seattle, including new public health funding and a project to provide at-home testing kits. Monday, March 9, 2020 A Biogen management meeting held in Boston in late February is at the center of Massachusetts’ outbreak of the novel coronavirus. As of Sunday, 23 cases in Massachusetts were tied to the meeting, according to local officials. That’s out of 28 confirmed or presumptive cases in the state. Friday, March 6, 2020 Dana-Farber Cancer Institute and MD Anderson Cancer Center have canceled all business travel. The travel bans are part of a wave of actions taken by healthcare organizations to limit the harm caused by the novel coronavirus now making inroads into the U.S. MedTech is about more than just building better medical devices. It’s also about technologies that, when applied with ingenuity, can help accelerate the entire biopharma enterprise. This year's Fierce 15 shows just how creative and dynamic the field of medical technology has become. Tuesday, March 10, 2020 Two people who were at Genentech's offices in South San Francisco earlier this month have since tested positive. ASCO is weighing going virtual. Bayer's employee tested negative, and more. Wednesday, March 11, 2020 Analysts at RBC are warning that a host of biopharmas could see their ongoing phase 3 trials hit by the novel coronavirus, as early-stage trials are particularly under threat. Monday, March 9, 2020 A China-based research team has mapped the route by which the coronavirus COVID-19 hijacks cells, while another team led by the University of Chicago mapped the 3D structure of Nsp15, a protein that's key to the virus' ability to replicate. Both groups hope their research will inspire new targeted treatments. Friday, March 6, 2020 In his first full year as Novartis CEO, Vas Narasimhan got a huge pay-packet boost—59% to be exact—thanks to strong financial performance and major portfolio milestones. As the company’s board sees it, the captain sailed the firm through 2019 with flying colors in almost all ways except for one: ethics. Tuesday, March 10, 2020 It’s been just over two years since INC Research and inVentiv came together in a $7.4 billion merger and rebranded as Syneos Health. Now, it’s looking for a sale. Tuesday, March 10, 2020 The recent GlaxoSmithKline and Pfizer consumer joint venture intends to sell off £1 billion worth of assets to raise some cash for operations and is losing no time in doing so. A plant in Canada with 400 employees is now on the front line of that effort while giving a Taiwan-based CDMO a North American manufacturing foothold. Friday, March 6, 2020 It’s one of those trials that bear some weight: It was meant to confirm a med’s first-ever approval, and industry watchers were looking for clues to assess the chance of future success. But in the case of AstraZeneca’s Imfinzi in bladder cancer, the immunotherapy has failed. Enrollment Showcase | | | Presented by: Global EMBA for Healthcare & the Life Sciences, University of Toronto Prepare to step up in your career, build the expertise you need to reshape your organization, and explore opportunities worldwide. Download the guide. |
|
|---|
|
Resources Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Metabolon Metabolomics can help you streamline your drug development process by providing the framework to make a stronger, more confident, and more valuable case for a molecule in a shorter timeframe. Sponsored by: Epsilon Download this e-book to learn 9 ways to enhance the customer experience within healthcare marketing. Sponsored by: Reprints Desk/Research Solutions 3 ways you may be overspending on scientific literature access, and how to fix them. Sponsored by: Baxter When different drug products are produced in shared facilities, potential for cross-contamination needs to be addressed. Outsourcing to a CMO with experience in multiproduct facilities can be an option. Sponsored by: WCG Metrics Champion Consortium Ineffective measurement could mean wasting both time and money. This whitepaper showcases a custom-built Metric Maturity Model that helps illustrate and define the process for measuring the right things the right way. Sponsored by: The Kinetix Group Read about the innovative ways payers are making smart moves in the healthcare game. Sponsored by: Clinical Ink Download this free white paper to learn how a BYOD ePRO approach is beneficial to your trial. Sponsored by: Catalent This whitepaper discusses the benefits of end-to-end solutions and share case studies on how flexible manufacturing strategies can accommodate the changing landscape of pharmaceutical products and help bring a drug to market. Sponsored by: Blue Matter Consulting White paper describing how a biopharma company can successfully differentiate an oncology product when the clinical profile alone is not enough to get the job done. Sponsored by: Catalent Learn how recent innovations in demand-led supply and direct-to-patient distribution are converging to create a next-generation clinical supply chain that is flexible, lean and most importantly patient-centric. Sponsored by: Catalent Pharma Solutions In this Q&A, four Catalent Biologics experts share how scale-up, regulatory expectations, demand forecasting and process validation all play a role in the success of a biologic when embarking upon the commercial manufacturing journey. |
|
